Coralie Bélanger

Supplementary Figure S5 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S5

Supplementary Figure S7 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S7

Supplementary Figure S3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S3

Supplementary Table 1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Supplementary Table 1

Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S2

Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S6

Supplementary Table 2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Supplementary Table 2

Supplementary Table 3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Supplementary Table 3

Supplementary Figure S1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S1

Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Figure S4

Final results of a first-in-human Phase I study of INA03, a novel CD71/TfR1-targeted antibody-drug conjugate, in patients with relapsed or refractory acute leukemia.

Sylvain Garciaz, Pierre Bories, Jean‐Marie Boher, Léonor Lopez Almeida et autres

Abstract Background: CD71/TfR1 (transferrin receptor 1) is highly expressed in proliferative malignancies, including acute leukemias, and is associated with poor prognosis. INA03 is a first-in-class antibody-drug conjugate (ADC), transferrin competitive, targeting CD71, designed to exploit the iron dependency and high metabolic demands …

fr (code pays fourni par la source)

Data from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment

Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Hervé Souchet et autres

Abstract Innovative strategies for enhancing efficacy and overcoming drug resistance in hematologic cancers, such as using antibody–drug conjugates (ADC), have shifted the paradigm of conventional care by delivering promising outcomes in cancer therapies with a significant reduction in the risk of relapse. …